Renoprotective effect of pioglitazone by the prevention of glomerular hyperfiltration through the possible restoration of altered macula densa signaling in rats with type 2 diabetic nephropathy

Nephron Exp Nephrol. 2012;122(3-4):83-94. doi: 10.1159/000348661. Epub 2013 Mar 29.

Abstract

Background/aims: Pioglitazone (PGZ), one of the thiazolidinediones, has been known to show renoprotective effects. In this study, we focused on the effect of PGZ on glomerular hyperfiltration (GHF), resultant glomerular injury and altered macula densa signaling as a cause of sustained GHF through modified tubuloglomerular feedback in rats with diabetic nephropathy.

Methods: Kidneys from 24-week-old male OLETF rats and LET rats, nondiabetic controls, were used for the experiment. PGZ was administered (10 mg/kg/day, p.o.) for 2 weeks from 22 to 24 weeks of age in some of the OLETF rats (OLETF+PGZ).

Results: Parameters relating GHF, kidney weight, creatinine clearance, urine albumin/creatinine ratio and glomerular surface were all increased in OLETF rats and partially restored in OLETF+PGZ rats. Expressions of desmin and TGF-β were also increased in OLETF rats and restored in OLETF+PGZ rats. The changes in TGF-β expression were confirmed to be independent of podocyte number. Finally, the immunoreactivity of neuronal nitric oxide synthase (nNOS) and cyclooxygenase 2 (COX-2) in the macula densa was assessed for the evaluation of macula densa signaling. Altered intensities of nNOS and COX-2 in OLETF rats were restored in OLETF+PGZ rats, which agreed with the gene expression analysis (nNOS: 100.2 ± 2.9% in LET, 64.2 ± 2.7% in OLETF, 87.4 ± 12.1% in OLETF+PGZ; COX-2: 100.8 ± 7.4% in LET, 249.2 ± 19.4% in OLETF, 179.9 ± 13.5% in OLETF+PGZ; n = 5) and the semiquantitative analysis of nNOS/COX-2-positive cells.

Conclusion: PGZ effectively attenuated the GHF and hyperfiltration-associated glomerular injury in diabetic nephropathy. The restoration of altered macula densa signaling might be involved in the renoprotective effect of PGZ.

MeSH terms

  • Animals
  • Cyclooxygenase 2 / metabolism
  • Desmin / biosynthesis
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / prevention & control
  • Juxtaglomerular Apparatus / drug effects
  • Juxtaglomerular Apparatus / physiology*
  • Kidney Glomerulus / drug effects*
  • Male
  • Nitric Oxide Synthase Type I / metabolism
  • Pioglitazone
  • Rats
  • Rats, Inbred OLETF
  • Signal Transduction
  • Thiazolidinediones / pharmacology
  • Thiazolidinediones / therapeutic use*
  • Transforming Growth Factor beta / biosynthesis

Substances

  • Desmin
  • Thiazolidinediones
  • Transforming Growth Factor beta
  • Nitric Oxide Synthase Type I
  • Nos1 protein, rat
  • Cyclooxygenase 2
  • Ptgs2 protein, rat
  • Pioglitazone